|Bid||11.92 x 800|
|Ask||14.97 x 1100|
|Day's Range||12.41 - 13.04|
|52 Week Range||5.14 - 18.55|
|Beta (3Y Monthly)||2.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.80|
Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company’s ongoing Phase 2 clinical trials of tazemetostat will be reported during oral presentations at medical meetings in June. Updated data from the fully enrolled cohort of epithelioid sarcoma patients in the company’s molecularly defined solid tumor program will be presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. Updated data from the fully enrolled cohorts of patients with follicular lymphoma, both with and without EZH2 activating mutations, will be reported at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.
The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points. SEC filings and hedge […]
Epizyme (EPZM) delivered earnings and revenue surprises of 17.02% and 601.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 39 cents per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...
Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for Second Quarter and Fourth Quarter 2019, Respectively
It is a pleasure to report that the Epizyme, Inc. (NASDAQ:EPZM) is up 39% in the last quarter. But over the last half decade, the stock has not performed well. In fact, the share price is down 39%, which falls well short o...
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced the closing of its two concurrent underwritten public offerings of 11,500,000 shares of its common stock and 350,000 shares of its non-voting Series A Convertible Preferred Stock, which includes the full exercise by the underwriters of their separate options in each of the respective offerings to purchase additional shares at the public offering price. The public offering price of each share of common stock was $11.50 and the public offering price of each share of Series A stock was $115.00. The aggregate gross proceeds to Epizyme from the offerings, before deducting underwriting discounts and offering expenses, are $172.50 million.
Rob Bazemore has been the CEO of Epizyme, Inc. (NASDAQ:EPZM) since 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that,Read More...
Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series A Convertible Preferred Stock. Epizyme anticipates the total gross proceeds from the offering (before deducting underwriting discounts and offering expenses) will be approximately $150 million, excluding any exercise of the underwriters' options to purchase additional shares and before deducting underwriting discounts and offering expenses. The public offering price of each share of common stock is $11.50 and the public offering price of each share of Series A stock is $115.00.
Epizyme, Inc. (EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten public offerings. The offerings are being made by means of separate preliminary prospectus supplements and are not contingent upon each other. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and preferred stock offered in the offering.
Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March inv
Two Successive Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for 2019
Fourth Quarter and Full-Year 2018 Financial Results: Management will host a conference call and webcast to discuss its fourth quarter and full year 2018 financial results and other business highlights at 8:30 a.m. ET on Tuesday, February 26, 2019. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 1088195.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Epizyme (EPZM) announces that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma.
Why Epizyme Stock Rose ~32% on January 4 ## Stock performance On January 4, Epizyme (EPZM) stock closed at $7.94, which represents ~32.78% growth from its prior close of $5.98 on January 3, 2019. On January 3, Epizyme stock fell 10.34% to reach $5.98 from its prior-day closing price of $6.67 on January 2. Epizyme stock fell from $12.55 at the close of market on December 29, 2017, to reach $6.16 on December 31, 2018, which was a ~51% decline in 2018. Epizyme’s price on January 4 is ~63% below its 52-week high of $21.4 on March 13, 2018. The company hit its 52-week low of $5.14 on December 24, 2018. ## Reason for stock price rise On January 4, Epizyme announced that it found a path for accelerated approval by the US FDA (Food and Drug Administration) of its investigational drug tazemetostat for the treatment of individuals with relapsed or refractory follicular lymphoma (or FL) who may be with or without EZH2 activating mutations. Epizyme already conducted a meeting with the FDA to discuss the FL registration strategy with the present patient population in the company’s ongoing phase 2 trial. After discussion with the FDA, the company specified the registration strategy for tazemetostat. The company can register patients in both types of EZH2 mutation and patients with wild-type FL with disease progression after two or more lines of therapy. Epizyme expects to submit an NDA (new drug application) to the FDA for the said indications by the fourth quarter of 2019. Epizyme already completed the enrollment of the phase 2 trial for the evaluation of safety and efficacy of tazemetostat for the said indications. Epizyme also anticipates submitting its first NDA to the FDA for tazemetostat for the treatment of individuals with epithelioid sarcoma under accelerated approval pathway in the second quarter of 2019. Epizyme has plans to initiate clinical trials for label expansion of tazemetostat and also evaluate the drug along with other combination therapies. Epizyme sees potential in the drug for the treatment of multiple cancer types. The company plans to initiate the study of tazemetostat for small-cell lung cancer, triple-negative breast cancer, ovarian cancer, and castration-resistant prostate cancer by the second half of 2019. ## Analysts’ recommendations Of the ten analysts tracking Epizyme in January 2019, four of them recommended a “strong buy,” while another four analysts recommended a “buy” rating. Two analysts recommended a “hold” rating for Epizyme in January 2019. The company had a consensus 12-month target price of $19.44, which represents a ~144.84% return on investment over the next 12 months.
CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month.
Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations. The company recently conducted a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss the FL registration strategy based on the current patient population in its ongoing Phase 2 clinical trial.
“October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being ’08 and the Crash of ’87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]